SG192444A1 - Materials and methods for suppressing and/or treating neurofibroma and related tumors - Google Patents

Materials and methods for suppressing and/or treating neurofibroma and related tumors Download PDF

Info

Publication number
SG192444A1
SG192444A1 SG2013049952A SG2013049952A SG192444A1 SG 192444 A1 SG192444 A1 SG 192444A1 SG 2013049952 A SG2013049952 A SG 2013049952A SG 2013049952 A SG2013049952 A SG 2013049952A SG 192444 A1 SG192444 A1 SG 192444A1
Authority
SG
Singapore
Prior art keywords
compound
dose
plexiform
patient
mice
Prior art date
Application number
SG2013049952A
Other languages
English (en)
Inventor
D Wade Clapp
David Ingram
feng-chun Yang
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41445287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG192444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of SG192444A1 publication Critical patent/SG192444A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG2013049952A 2008-06-27 2009-06-25 Materials and methods for suppressing and/or treating neurofibroma and related tumors SG192444A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7618508P 2008-06-27 2008-06-27
US10365008P 2008-10-08 2008-10-08

Publications (1)

Publication Number Publication Date
SG192444A1 true SG192444A1 (en) 2013-08-30

Family

ID=41445287

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013049952A SG192444A1 (en) 2008-06-27 2009-06-25 Materials and methods for suppressing and/or treating neurofibroma and related tumors

Country Status (18)

Country Link
US (3) US20110195975A1 (fr)
EP (1) EP2291186A4 (fr)
JP (2) JP2011526292A (fr)
KR (2) KR20160011713A (fr)
CN (2) CN102099038A (fr)
AU (1) AU2009262214B9 (fr)
BR (1) BRPI0914618A2 (fr)
CA (1) CA2727737C (fr)
CL (1) CL2009001486A1 (fr)
EA (2) EA022611B1 (fr)
IL (1) IL209973A (fr)
MA (1) MA32419B1 (fr)
MX (1) MX2010013918A (fr)
NZ (1) NZ590076A (fr)
SG (1) SG192444A1 (fr)
TW (1) TWI508728B (fr)
WO (1) WO2009158447A2 (fr)
ZA (1) ZA201009066B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CN113975386A (zh) * 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
KR101894769B1 (ko) 2017-12-05 2018-09-04 아주대학교산학협력단 siRNA를 포함하는 신경섬유육종 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2439440A1 (fr) * 2002-09-05 2004-03-05 Emory University Traitement de tumeurs associees a la sclerose tubereuse
WO2007065898A1 (fr) * 2005-12-06 2007-06-14 Novartis Ag Dérivés de pyrimidylaminobenzamide pour le traitement d'une neurofibromatose
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase

Also Published As

Publication number Publication date
MA32419B1 (fr) 2011-06-01
NZ590076A (en) 2012-11-30
JP2015187104A (ja) 2015-10-29
EA022611B1 (ru) 2016-02-29
TWI508728B (zh) 2015-11-21
WO2009158447A9 (fr) 2010-03-25
IL209973A (en) 2015-11-30
WO2009158447A2 (fr) 2009-12-30
AU2009262214B2 (en) 2014-12-11
KR20160011713A (ko) 2016-02-01
US20110195975A1 (en) 2011-08-11
CN105726542A (zh) 2016-07-06
EA201500525A1 (ru) 2015-11-30
MX2010013918A (es) 2011-07-04
EA201071340A1 (ru) 2011-12-30
US8933082B2 (en) 2015-01-13
US20140121214A1 (en) 2014-05-01
AU2009262214B9 (en) 2015-04-30
CN102099038A (zh) 2011-06-15
KR20110044945A (ko) 2011-05-03
CA2727737A1 (fr) 2009-12-30
ZA201009066B (en) 2011-08-31
IL209973A0 (en) 2011-02-28
JP2011526292A (ja) 2011-10-06
US20150072992A1 (en) 2015-03-12
BRPI0914618A2 (pt) 2017-06-06
TW201006472A (en) 2010-02-16
AU2009262214A1 (en) 2009-12-30
EP2291186A4 (fr) 2011-06-22
CL2009001486A1 (es) 2010-04-16
CA2727737C (fr) 2016-08-23
EP2291186A2 (fr) 2011-03-09
US9345704B2 (en) 2016-05-24

Similar Documents

Publication Publication Date Title
Outtandy et al. Zebrafish as a model for kidney function and disease
Nishiguchi et al. Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179
Yu-Wai-Man et al. A neurodegenerative perspective on mitochondrial optic neuropathies
Singh et al. Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation
Meyerson et al. Leber hereditary optic neuropathy: current perspectives
Ratican et al. Progress in gene therapy to prevent retinal ganglion cell loss in glaucoma and Leber’s hereditary optic neuropathy
Singh Grewal et al. Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies
Yan et al. Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice
Komáromy et al. Equine Multiple Congenital Ocular Anomalies (MCOA) syndrome in PMEL17 (Silver) mutant ponies: five cases
SG192444A1 (en) Materials and methods for suppressing and/or treating neurofibroma and related tumors
Ma et al. The safe recipient of SSC transplantation prepared by heat shock with busulfan treatment in mice
Liu et al. Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis
Narfström et al. The domestic cat as a large animal model for characterization of disease and therapeutic intervention in hereditary retinal blindness
Lartey et al. A temporally‐restricted pattern of endothelial cell collagen 4 alpha 1 expression during embryonic development determined with a novel knockin Col4a1‐P2A‐eGFP mouse line
Cring et al. Ectopic expression of BBS1 rescues male infertility, but not retinal degeneration, in a BBS1 mouse model
Koulisis et al. Precision therapy for inherited retinal disease: at the forefront of genomic medicine
De Oliveira et al. The long‐term outcomes of standing superficial keratectomy as the sole treatment of corneal B‐cell lymphoma in five horses in the UK: Clinical, histopathology, immunohistochemical and molecular findings
Kumari et al. The role of microglia in inherited retinal diseases
Mao et al. Ocular characteristics of patients with Leber congenital amaurosis 6 caused by pathogenic RPGRIP1 gene variation in a Chinese cohort
Caselli et al. High‐dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: Report of five cases
De Sutter et al. Occurrence of macular neovascularization after retinal pigment epithelium-choroid translocation surgery to treat complicated age-related macular degeneration: incidence, management, and outcome
Wang et al. Zeb1 Facilitates Nitrogen Mustard–Induced Corneal Epithelial Wound Healing by Maintaining Epithelial Renewability
AU2015201261A1 (en) Materials and Methods for Suppressing and/or Treating Neurofibroma and Related Tumors
Walder-Christensen et al. Synaptic editing of frontostriatal circuitry prevents excessive grooming in SAPAP3-deficient mice
Tschulakow et al. The radioprotector ortho-phospho-L-tyrosine (pTyr) attenuates the side effects of fractionated irradiation in retinoblastoma mouse models but also decreases the local tumour control